The effect of aurothiomalate on the oxidative burst of polymorphonuclear leukocytes varies with the quantity of drug in myocrisin ampoules.
The antirheumatic drug, sodium aurothiomalate (GSTM), is not a well defined substance and chemical changes occur in the heat sterilization of the commercial ampoules (Myocrisin). In a comparison of the pharmacological properties of Myocrisin with freshly prepared solutions of GSTM, their effects on the chemiluminescence of polymorphonuclear leukocytes (PMN) activated by phorbol myristate acetate (PMA) were studied. Chemiluminescence was measured in the presence of GSTM from solid material and from Myocrisin ampoules. Myocrisin from 1 and 5 mg ampoules and GSTM in fresh solutions heated at 95 degrees C for 30 min inhibited chemiluminescence, whereas Myocrisin from the higher strength (10-50 mg) ampoules and GSTM in unheated solutions showed no effect at low concentrations and enhancement of chemiluminescence at higher concentrations. Since the gold complexes present in the different strength Myocrisin ampoules do not have identical biological effects, the use of GSTM in investigational studies should involve consideration of its source.
Rudkowski
R
R
Prince of Wales Children's Hospital, Randwick, NSW, Australia.
Graham
G G
GG
Ziegler
J B
JB
Champion
G D
GD
D002214:Capsules; D004305:Dose-Response Relationship, Drug; D006052:Gold Sodium Thiomalate / Q000494:pharmacology*; D006801:Humans; D008163:Luminescent Measurements; D008165:Luminol / Q000493:pharmacokinetics; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D010084:Oxidation-Reduction / Q000187:drug effects; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors
D002214:Capsules; D006052:Gold Sodium Thiomalate; D008165:Luminol; D013755:Tetradecanoylphorbol Acetate